147 related articles for article (PubMed ID: 8806695)
1. Activated N-ras oncogene and N-ras proto-oncogene act through the same pathway for in vivo tumorigenesis.
Mangues R; Symmans WF; Lu S; Schwartz S; Pellicer A
Oncogene; 1996 Sep; 13(5):1053-63. PubMed ID: 8806695
[TBL] [Abstract][Full Text] [Related]
2. An overexpressed N-ras proto-oncogene cooperates with N-methylnitrosourea in mouse mammary carcinogenesis.
Mangues R; Kahn JM; Seidman I; Pellicer A
Cancer Res; 1994 Dec; 54(24):6395-401. PubMed ID: 7987834
[TBL] [Abstract][Full Text] [Related]
3. The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice.
Elson A; Deng C; Campos-Torres J; Donehower LA; Leder P
Oncogene; 1995 Jul; 11(1):181-90. PubMed ID: 7624126
[TBL] [Abstract][Full Text] [Related]
4. Tumorigenesis and male sterility in transgenic mice expressing a MMTV/N-ras oncogene.
Mangues R; Seidman I; Pellicer A; Gordon JW
Oncogene; 1990 Oct; 5(10):1491-7. PubMed ID: 2174525
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice.
Mangues R; Corral T; Kohl NE; Symmans WF; Lu S; Malumbres M; Gibbs JB; Oliff A; Pellicer A
Cancer Res; 1998 Mar; 58(6):1253-9. PubMed ID: 9515813
[TBL] [Abstract][Full Text] [Related]
6. The CD2-scl transgene alters the phenotype and frequency of T-lymphomas in N-ras transgenic or p53 deficient mice.
Curtis DJ; Robb L; Strasser A; Begley CG
Oncogene; 1997 Dec; 15(24):2975-83. PubMed ID: 9416841
[TBL] [Abstract][Full Text] [Related]
7. MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice.
Zhou H; Chen WD; Qin X; Lee K; Liu L; Markowitz SD; Gerson SL
Oncogene; 2001 Sep; 20(42):6009-17. PubMed ID: 11593408
[TBL] [Abstract][Full Text] [Related]
8. Preferential activation of Fgf8 by proviral insertion in mammary tumors of Wnt1 transgenic mice.
Kapoun AM; Shackleford GM
Oncogene; 1997 Jun; 14(24):2985-9. PubMed ID: 9205106
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the N-ras proto-oncogene, not somatic mutational activation, associated with malignant tumors in transgenic mice.
Mangues R; Seidman I; Gordon JW; Pellicer A
Oncogene; 1992 Oct; 7(10):2073-6. PubMed ID: 1328989
[TBL] [Abstract][Full Text] [Related]
10. MMTV-induced mammary tumorigenesis: gene discovery, progression to malignancy and cellular pathways.
Callahan R; Smith GH
Oncogene; 2000 Feb; 19(8):992-1001. PubMed ID: 10713682
[TBL] [Abstract][Full Text] [Related]
11. Structural analysis of the ras transgene in MMTV/v-Ha-ras transgenic mice.
DeWille JW; Farmer SJ
Lab Anim Sci; 1994 Apr; 44(2):131-4. PubMed ID: 8028274
[TBL] [Abstract][Full Text] [Related]
12. Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas.
Theodorou V; Boer M; Weigelt B; Jonkers J; van der Valk M; Hilkens J
Oncogene; 2004 Aug; 23(36):6047-55. PubMed ID: 15208658
[TBL] [Abstract][Full Text] [Related]
13. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
[TBL] [Abstract][Full Text] [Related]
14. Differential regulation of cell cycle characteristics and apoptosis in MMTV-myc and MMTV-ras mouse mammary tumors.
Hundley JE; Koester SK; Troyer DA; Hilsenbeck SG; Barrington RE; Windle JJ
Cancer Res; 1997 Feb; 57(4):600-3. PubMed ID: 9044833
[TBL] [Abstract][Full Text] [Related]
15. NF1 inactivation cooperates with N-ras in in vivo lymphogenesis activating Erk by a mechanism independent of its Ras-GTPase accelerating activity.
Mangues R; Corral T; Lu S; Symmans WF; Liu L; Pellicer A
Oncogene; 1998 Oct; 17(13):1705-16. PubMed ID: 9796699
[TBL] [Abstract][Full Text] [Related]
16. Incidence of c-Ki-ras activation in N-methyl-N-nitrosourea-induced mammary carcinomas in pituitary-isografted mice.
Guzman RC; Osborn RC; Swanson SM; Sakthivel R; Hwang SI; Miyamoto S; Nandi S
Cancer Res; 1992 Oct; 52(20):5732-7. PubMed ID: 1394197
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis.
Sarkisian CJ; Keister BA; Stairs DB; Boxer RB; Moody SE; Chodosh LA
Nat Cell Biol; 2007 May; 9(5):493-505. PubMed ID: 17450133
[TBL] [Abstract][Full Text] [Related]
18. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
19. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability.
McCormack SJ; Weaver Z; Deming S; Natarajan G; Torri J; Johnson MD; Liyanage M; Ried T; Dickson RB
Oncogene; 1998 May; 16(21):2755-66. PubMed ID: 9652742
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties.
Bearss DJ; Lee RJ; Troyer DA; Pestell RG; Windle JJ
Cancer Res; 2002 Apr; 62(7):2077-84. PubMed ID: 11929828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
